AtriCure Q2 revenue beats estimates

Overview

• U.S. surgical device maker's Q2 revenue grew 13%, beating analyst expectations

• Adjusted EPS for Q2 beat consensus at $0.18

• Adjusted EBITDA rose 78% yr/yr, beating analyst expectations

Outlook

• AtriCure projects 2026 revenue of $602 mln to $610 mln

• Company expects 2026 adjusted EBITDA of $85 mln to $89 mln

• AtriCure sees 2026 net income per share at $0.05 to $0.13 and adjusted EPS at $0.24 to $0.32

Result Drivers

• PAIN MANAGEMENT GROWTH - Sales of cryoSPHERE MAX probe for post-operative pain management drove U.S. revenue growth

• APPENDAGE MANAGEMENT DEVICES - Higher sales of AtriClip FLEX-Mini and PRO-Mini devices contributed to revenue gains

• GROSS MARGIN IMPROVEMENT - Gross margin rose due to favorable product and geographic mix and manufacturing efficiencies

Company press release: ID:nBw79hrlFa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies distribution peer group is "buy"

• Wall Street's median 12-month price target for AtriCure Inc is $50.00, about 49.2% above its July 22 closing price of $33.52

• The stock recently traded at 157 times the next 12-month earnings vs. a P/E of 231 three months ago

Reuters Recommended Reads

• July 23 - Novocure Q2 revenue beats, lifts 2026 outlook

• July 23 - Utah Medical Q2 revenue falls 14% on lost customers

• July 21 - PolyPid, Azurity sign surgical site infection drug deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)